Estrogen replacement therapy withdrawal and regression of metastatic breast cancer

Madhav V. Dhodapkar; James N. Ingle; David L. Ahmann

doi:10.1002/1097-0142(19950101)75:1<43::AID-CNCR2820750109>3.0.CO;2-#

Estrogen replacement therapy withdrawal and regression of metastatic breast cancer

Madhav V. Dhodapkar, James N. Ingle, David L. Ahmann

Medical Oncology

Research output: Contribution to journal › Article › peer-review

65 Scopus citations

Abstract

Background. Data regarding the effects of estrogen replacement therapy (ERT) and its withdrawal in patients with breast cancer are limited. Methods. Four cases were observed involving estrogen replacement therapy withdrawal as management of metastatic breast cancer. Results. Three patients with a history of primary breast cancer developed metastatic disease while on ERT. A fourth patient presented with metastatic breast cancer while on ERT. Withdrawal of this “physiologic” ERT alone as the only therapeutic intervention resulted in regression of metastatic disease in all four patients. Conclusions. In patients receiving ERT who develop metastatic breast cancer, withdrawal of ERT alone is a therapeutic option. Awareness of this phenomenon may be of value in management of these patients. The role of ERT and value of ERT withdrawal in patients with breast cancer deserve further study.

Original language	English (US)
Pages (from-to)	43-46
Number of pages	4
Journal	Cancer
Volume	75
Issue number	1
DOIs	https://doi.org/10.1002/1097-0142(19950101)75:1<43::AID-CNCR2820750109>3.0.CO;2-#
State	Published - Jan 1 1995

Keywords

estrogen replacement therapy
metastatic breast cancer
withdrawal response

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19950101)75:1<43::AID-CNCR2820750109>3.0.CO;2-#

Cite this

@article{8ae4c586581e445d9b67b71a85dfdb94,

title = "Estrogen replacement therapy withdrawal and regression of metastatic breast cancer",

abstract = "Background. Data regarding the effects of estrogen replacement therapy (ERT) and its withdrawal in patients with breast cancer are limited. Methods. Four cases were observed involving estrogen replacement therapy withdrawal as management of metastatic breast cancer. Results. Three patients with a history of primary breast cancer developed metastatic disease while on ERT. A fourth patient presented with metastatic breast cancer while on ERT. Withdrawal of this “physiologic” ERT alone as the only therapeutic intervention resulted in regression of metastatic disease in all four patients. Conclusions. In patients receiving ERT who develop metastatic breast cancer, withdrawal of ERT alone is a therapeutic option. Awareness of this phenomenon may be of value in management of these patients. The role of ERT and value of ERT withdrawal in patients with breast cancer deserve further study.",

keywords = "estrogen replacement therapy, metastatic breast cancer, withdrawal response",

author = "Dhodapkar, {Madhav V.} and Ingle, {James N.} and Ahmann, {David L.}",

year = "1995",

month = jan,

day = "1",

doi = "10.1002/1097-0142(19950101)75:1<43::AID-CNCR2820750109>3.0.CO;2-#",

language = "English (US)",

volume = "75",

pages = "43--46",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Estrogen replacement therapy withdrawal and regression of metastatic breast cancer

AU - Dhodapkar, Madhav V.

AU - Ingle, James N.

AU - Ahmann, David L.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Background. Data regarding the effects of estrogen replacement therapy (ERT) and its withdrawal in patients with breast cancer are limited. Methods. Four cases were observed involving estrogen replacement therapy withdrawal as management of metastatic breast cancer. Results. Three patients with a history of primary breast cancer developed metastatic disease while on ERT. A fourth patient presented with metastatic breast cancer while on ERT. Withdrawal of this “physiologic” ERT alone as the only therapeutic intervention resulted in regression of metastatic disease in all four patients. Conclusions. In patients receiving ERT who develop metastatic breast cancer, withdrawal of ERT alone is a therapeutic option. Awareness of this phenomenon may be of value in management of these patients. The role of ERT and value of ERT withdrawal in patients with breast cancer deserve further study.

AB - Background. Data regarding the effects of estrogen replacement therapy (ERT) and its withdrawal in patients with breast cancer are limited. Methods. Four cases were observed involving estrogen replacement therapy withdrawal as management of metastatic breast cancer. Results. Three patients with a history of primary breast cancer developed metastatic disease while on ERT. A fourth patient presented with metastatic breast cancer while on ERT. Withdrawal of this “physiologic” ERT alone as the only therapeutic intervention resulted in regression of metastatic disease in all four patients. Conclusions. In patients receiving ERT who develop metastatic breast cancer, withdrawal of ERT alone is a therapeutic option. Awareness of this phenomenon may be of value in management of these patients. The role of ERT and value of ERT withdrawal in patients with breast cancer deserve further study.

KW - estrogen replacement therapy

KW - metastatic breast cancer

KW - withdrawal response

UR - http://www.scopus.com/inward/record.url?scp=0028839029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028839029&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19950101)75:1<43::AID-CNCR2820750109>3.0.CO;2-#

DO - 10.1002/1097-0142(19950101)75:1<43::AID-CNCR2820750109>3.0.CO;2-#

M3 - Article

C2 - 7804976

AN - SCOPUS:0028839029

SN - 0008-543X

VL - 75

SP - 43

EP - 46

JO - Cancer

JF - Cancer

IS - 1

ER -

Estrogen replacement therapy withdrawal and regression of metastatic breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this